NASDAQ:FATE

Fate Therapeutics Stock Forecast, Price & News

$84.22
+6.04 (+7.73 %)
(As of 04/21/2021 03:59 PM ET)
Add
Compare
Today's Range
$75.88
Now: $84.22
$84.34
50-Day Range
$72.16
MA: $83.90
$97.66
52-Week Range
$25.60
Now: $84.22
$121.16
Volume45,644 shs
Average Volume1.05 million shs
Market Capitalization$7.90 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800
Employees279
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.68 million
Book Value$3.24 per share

Profitability

Net Income$-98,150,000.00
Net Margins-810.13%

Miscellaneous

Market Cap$7.90 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

Headlines

Fate Therapeutics (NASDAQ:FATE) Trading 5.2% Higher
April 13, 2021 |  americanbankingnews.com
Fate Therapeutics (NASDAQ:FATE) Stock Price Down 6.4%
April 12, 2021 |  americanbankingnews.com
Is Fate Therapeutics Stock A Buy or Sell?
April 6, 2021 |  finance.yahoo.com
Fate Therapeutics (NASDAQ:FATE) Shares Gap Down to $83.66
April 6, 2021 |  americanbankingnews.com
FATE Crosses Above Average Analyst Target
March 2, 2021 |  nasdaq.com
Fate Therapeutics: Q4 Earnings Insights
February 24, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.80 out of 5 stars

Medical Sector

154th out of 2,025 stocks

Biological Products, Except Diagnostic Industry

19th out of 177 stocks

Analyst Opinion: 4.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$84.22
+6.04 (+7.73 %)
(As of 04/21/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

Is Fate Therapeutics a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Fate Therapeutics stock.
View analyst ratings for Fate Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Fate Therapeutics?

Wall Street analysts have given Fate Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fate Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Fate Therapeutics
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) posted its earnings results on Wednesday, February, 24th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $0.23. The biopharmaceutical company earned $15.90 million during the quarter, compared to analyst estimates of $5.42 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 35.51% and a negative net margin of 810.13%.
View Fate Therapeutics' earnings history
.

How has Fate Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FATE shares have increased by 250.4% and is now trading at $83.35.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for FATE?

13 brokerages have issued 12-month price objectives for Fate Therapeutics' shares. Their forecasts range from $76.00 to $135.00. On average, they anticipate Fate Therapeutics' share price to reach $108.31 in the next year. This suggests a possible upside of 29.9% from the stock's current price.
View analysts' price targets for Fate Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the following people:
  • Mr. J. Scott Wolchko, Founder, CEO, Pres & Director (Age 51, Pay $850.5k)
  • Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 53, Pay $525.94k)
  • Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 48, Pay $525.94k)
  • Dr. Bahram Valamehr Ph.D., Chief R&D Officer (Age 44, Pay $525.94k)
  • Mr. Edward J. Dulac III, CFO & Principal Accounting Officer (Age 46)
  • Dr. Wen Bo Wang, Sr. VP of Technical Operations
  • Mr. Jim Beitel M.B.A., Sr. VP of Corp. Devel.
  • Dr. Sarah Cooley, Sr. VP of Clinical Translation
  • Dr. Yu-Waye Chu M.D., Sr. VP of Clinical Devel.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics CEO Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among Fate Therapeutics' employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Fate Therapeutics' key competitors?

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), 1877 (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Epiq Partners LLC (0.05%), EFG Asset Management Americas Corp. (0.04%), Exchange Traded Concepts LLC (0.00%) and Pacer Advisors Inc. (0.00%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko, Redmile Group, Llc and Yu-Waye Chu.
View institutional ownership trends for Fate Therapeutics
.

Which institutional investors are selling Fate Therapeutics stock?

FATE stock was sold by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and Pacer Advisors Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko, and Yu-Waye Chu.
View insider buying and selling activity for Fate Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Fate Therapeutics stock?

FATE stock was purchased by a variety of institutional investors in the last quarter, including EFG Asset Management Americas Corp., and Epiq Partners LLC.
View insider buying and selling activity for Fate Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $83.35.

How much money does Fate Therapeutics make?

Fate Therapeutics has a market capitalization of $7.82 billion and generates $10.68 million in revenue each year. The biopharmaceutical company earns $-98,150,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

How many employees does Fate Therapeutics have?

Fate Therapeutics employs 279 workers across the globe.

What is Fate Therapeutics' official website?

The official website for Fate Therapeutics is www.fatetherapeutics.com.

Where are Fate Therapeutics' headquarters?

Fate Therapeutics is headquartered at 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]


This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.